Atlas Trials

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

Clinical trial NCT06305702 · COMPLETED

Trial details

NCT number
NCT06305702
Sponsor
Liaoning Cancer Hospital & Institute
Status
COMPLETED
Study type
OBSERVATIONAL
HER2-positive Metastatic Breast Cancer
Start date
2022-07-01
Primary completion
2023-12-31
Enrollment
500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.